SystImmune公司将在2025年ESMO乳腺癌会议上展示izalontamab brengitecan（iza-bren）在局部晚期或转移性乳腺癌中的最新数据-动脉网

SystImmune, Inc. to Present Updated izalontamab brengitecan (iza-bren) Data in Locally Advanced or Metastatic Breast Cancer at ESMO Breast 2025

CISION 等信源发布 2025-05-09 19:00



可切换为仅中文







- Updated safety & efficacy in Locally Advanced or Metastatic Breast Cancer will be presented from a Ph1 clinical study evaluating

- 局部晚期或转移性乳腺癌的更新安全性和有效性数据将从一项评估的Ph1临床研究中呈现

iza-bren, an EGFRxHER3 bispecific topoisomerase inhibitor- based antibody-drug conjugate (ADC)

iza-bren，一种基于EGFRxHER3双特异性拓扑异构酶抑制剂的抗体药物偶联物（ADC）

REDMOND, Wash.

红蒙德，华盛顿州

，

May 9, 2025

2025年5月9日

/PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that one abstract on izalontamab brengitecan (iza-bren), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC) will be presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress taking place .

/PRNewswire/ -- 临床阶段生物技术公司SystImmune今日宣布，一篇关于izalontamab brengitecan（iza-bren）的摘要将在欧洲肿瘤内科学会（ESMO）乳腺癌2025年年会上公布。izalontamab brengitecan是一种潜在的首创EGFRxHER3双特异性抗体药物偶联物（ADC）。

May 14

5月14日

–

May 17

5月17日

在

Munich, Germany

德国慕尼黑

. Iza-bren is being jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement.

Iza-bren 是由 SystImmune 和百时美施贵宝根据一项合作与独家许可协议共同开发的。

Data will be presented at the meeting from an ongoing Ph1 clinical trial of iza-bren in patients with locally advanced or metastatic HER2- Breast Cancer. Additional subgroup analysis in previously disclosed data at SABCS 2024 shows encouraging efficacy for iza-bren across all HER2 levels in HER2- Breast Cancer patients including HER2 0 patients.

在局部晚期或转移性HER2阴性乳腺癌患者中进行的iza-bren Ph1临床试验的持续数据将在会议上展示。在SABCS 2024上公布的先前数据的额外亚组分析显示，iza-bren在所有HER2水平的HER2阴性乳腺癌患者中，包括HER2 0患者，均显示出令人鼓舞的疗效。

These data highlights continued progress in iza-bren clinical development and builds upon the previously reported clinical data in breast cancer patients at SABCS in 2024..

这些数据突显了iza-bren在临床开发中的持续进展，并基于2024年SABCS上先前报告的乳腺癌患者的临床数据。

'These data continue to support our conviction that iza-bren demonstrates strong clinical efficacy across a wide variety of tumors such as breast cancer including HER2 negative breast cancer with a manageable safety profile,' said Jonathan Cheng, M.D., CMO of SystImmune. 'This positions iza-bren as an important therapeutic option that may address the unmet medical needs of patients with limited treatment options.

“这些数据继续支持我们的信念，即iza-bren在包括乳腺癌（包括HER2阴性乳腺癌）在内的多种肿瘤中表现出强大的临床疗效，并具有可控的安全性，”SystImmune首席医学官Jonathan Cheng博士表示。“这使iza-bren成为一种重要的治疗选择，可能满足那些治疗选择有限的患者的未满足医疗需求。”

We are committed to advancing this therapy through clinical trials, exploring its potential not only as a monotherapy but also in combination with other agents, so as to improve outcomes for cancer patients globally.'.

我们致力于通过临床试验推进这种疗法，不仅探索其作为单一疗法的潜力，还探索其与其他药物联合使用的潜力，从而改善全球癌症患者的治疗效果。'

Details on the presentations at ESMO Breast are below:

以下是ESMO乳腺癌会议上的报告详情：

Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Breast Cancer (BC)

伊扎布伦（BL-B01D1）I期研究，一种EGFR x HER3双特异性抗体药物偶联物（ADC），用于局部晚期或转移性乳腺癌（BC）患者

Presentation No:

演示编号：

302MO

Session Title:

会议标题：

Mini Oral Session 2

小型口头报告会 2

Speaker:

发言人：

Yiqun Du

杜一群

(

Shanghai, China

中国上海

)

Session Date & Time:

会议日期与时间：

Friday, May 16

5月16日，星期五

, 2025,

，2025，

8:20 AM-10:10 AM CEST

上午8:20 - 上午10:10 欧洲中部夏令时间

About iza-bren

关于iza-bren

The company is developing iza-bren, a bispecific antibody-drug conjugate (ADC) that targets both EGFR and HER3. These proteins are highly expressed in most epithelial tumors. The tetravalent iza-bren has two binding domains for distinct Growth Factor Receptors that drive cancer cell proliferation and survival.

公司正在开发一种双特异性抗体药物偶联物（ADC）iza-bren，它同时靶向EGFR和HER3。这些蛋白在大多数上皮肿瘤中高度表达。四价的iza-bren拥有两个针对不同生长因子受体的结合域，这些受体驱动癌细胞的增殖和存活。

Iza-bren blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. Upon antibody mediated internalization, iza-bren is trafficked to cancer cell lysosomes and liberates its therapeutic payload that induces genotoxic stress activating pathways leading to cancer cell death..

Iza-bren 阻断 EGFR 和 HER3 向癌细胞传递信号，减少增殖和存活信号。在抗体介导的内化过程中，iza-bren 被转运到癌细胞的溶酶体中，并释放其治疗载荷，诱导基因毒性应激激活途径，从而导致癌细胞死亡。

About SystImmune

关于SystImmune

SystImmune is a clinical-stage biopharmaceutical company located in

SystImmune是一家临床阶段的生物制药公司，位于

Redmond, WA.

华盛顿州雷德蒙德。

It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has several assets in various stages of clinical trials for solid tumor and hematologic indications.

该公司专注于利用其成熟的药物开发平台开发创新的癌症治疗方法，重点关注双特异性、多特异性抗体以及抗体药物偶联物（ADC）。SystImmune拥有多个处于不同临床试验阶段的资产，用于实体瘤和血液学适应症。

Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development..

除了正在进行的临床试验外，SystImmune还拥有一个强大的癌症治疗药物的临床前管线，这些药物处于发现或IND启用阶段，代表着尖端的生物制剂开发。

Forward-Looking Statements

前瞻性声明

Any research and development information provided by SystImmune is intended for general information purposes only. Such information is not intended to provide complete medical information. We do not offer patient-specific treatment advice and if you have medical conditions, please see your medical doctor or healthcare provider..

SystImmune 提供的任何研发信息仅供参考。此类信息并非旨在提供完整的医学信息。我们不提供针对患者的治疗建议，如果您有医疗状况，请咨询您的医生或医疗服务提供者。

This press release may contain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which reflects the expectations regarding the company's goals, strategies, results of operations, performance, business prospects, and opportunities, including but not limited to the ability to gain Investigational New Drug status for the resulting new product and the ability to develop a successful formulation.

本新闻稿可能包含1933年《证券法》第27A条（经修订）、1934年《证券交易法》第21E条以及1995年《私人证券诉讼改革法》所指的前瞻性陈述，反映了对公司目标、战略、经营成果、业绩、业务前景和机会的预期，包括但不限于使相关新产品获得研究性新药地位的能力以及成功开发配方的能力。

Terms such as 'anticipates,' 'believes,' 'expects,' 'estimates,' 'could,' 'intends,' 'may,' 'plans,' 'potential,' 'projects,' 'will,' 'would' and other similar expressions, or the negative of these terms, are generally indicative of forward-looking statements..

诸如“预期”、“相信”、“预计”、“估计”、“可能”、“打算”、“或许”、“计划”、“潜力”、“项目”、“将”、“会”等术语，或这些术语的否定形式，通常表示前瞻性陈述。

While SystImmune, Inc. believes that expectations expressed in the forward-looking statements are based on the company's reasonable assumptions and beliefs in light of the information available to the company at the time such statements are made, it cannot give assurance that such forward-looking statements will prove to have been correct.

虽然 SystImmune 公司认为，前瞻性陈述中表达的预期是基于公司在作出此类陈述时根据可获得的信息所作出的合理假设和信念，但公司无法保证这些前瞻性陈述最终将被证明是正确的。

Such forward-looking statements are not fact and are subject to uncertainties and other factors that could cause actual results to differ materially from such statements. We undertake no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events..

此类前瞻性陈述并非事实，且受制于可能导致实际结果与这些陈述存在重大差异的不确定性和其他因素。我们不承担更新本新闻稿中包含的任何前瞻性陈述的义务，以反映其日期之后发生的事件或情况，或反映未预期事件的发生。

For additional information about the company, please visit

有关公司的更多信息，请访问

https://systimmune.com/

。

Media Contact:

媒体联系人：

Jason Edwards

杰森·爱德华兹

，

jason.edwards@systimmune.com

SOURCE SystImmune, Inc.